Abstract
In the present paper 25 known thermolysin inhibitors were docked into thermolysin using the Internal Coordinate Mechanics (ICM™) software. Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout™ program. The docking studies indicated that all 25 inhibitors coordinated the catalytic zinc in bidentate or monodentate geometry. A ‘three-point’ pharmacophore model was proposed which consisted of a hydrophobic group, a negative ionizable group and a hydrogen bond acceptor group. Finally the pharmacophore model has been tested against a small compound library containing 18 highly, moderately, less active as well as inactive compounds. The screening indicated that the pharmacophore model could, identify highly active compounds in front of inactive or less active ones.
Keywords: Thermolysin inhibitors, molecular docking, pharmacophore models, antibacterial drugs, antihypertensive drugs, thermolysin, Listeeria, Clostridium, Staphyloccus, Pseudomonas, Vibrio
Mini-Reviews in Medicinal Chemistry
Title:Binding Modes and Pharmacophore Modelling of Thermolysin Inhibitors
Volume: 12 Issue: 6
Author(s): M. T.H. Khan, Y. Wuxiuer and I. Sylte
Affiliation:
Keywords: Thermolysin inhibitors, molecular docking, pharmacophore models, antibacterial drugs, antihypertensive drugs, thermolysin, Listeeria, Clostridium, Staphyloccus, Pseudomonas, Vibrio
Abstract: In the present paper 25 known thermolysin inhibitors were docked into thermolysin using the Internal Coordinate Mechanics (ICM™) software. Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout™ program. The docking studies indicated that all 25 inhibitors coordinated the catalytic zinc in bidentate or monodentate geometry. A ‘three-point’ pharmacophore model was proposed which consisted of a hydrophobic group, a negative ionizable group and a hydrogen bond acceptor group. Finally the pharmacophore model has been tested against a small compound library containing 18 highly, moderately, less active as well as inactive compounds. The screening indicated that the pharmacophore model could, identify highly active compounds in front of inactive or less active ones.
Export Options
About this article
Cite this article as:
T.H. Khan M., Wuxiuer Y. and Sylte I., Binding Modes and Pharmacophore Modelling of Thermolysin Inhibitors, Mini-Reviews in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/138955712800493799
DOI https://dx.doi.org/10.2174/138955712800493799 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models
Current Pharmaceutical Biotechnology Angiotensin-(1-7), Angiotensin-Converting Enzyme 2 and Mas Receptor in Rat Polycystic Ovaries
Protein & Peptide Letters Neurotoxicity of Ecstasy (MDMA): An Overview
Current Pharmaceutical Biotechnology Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy An Impact of Lifestyle Modification on Insulin Resistance in Hypertensive Patients with Metabolic Syndrome
Current Hypertension Reviews Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation
Mini-Reviews in Medicinal Chemistry Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Formulation, Characterization and In Vivo Evaluation of Self-Nanoemulsifying Drug Delivery System for Oral Delivery of Valsartan
Current Nanoscience Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Analytical Techniques for the Estimation of Perindopril Erbumine: A Review
Current Pharmaceutical Analysis Cerebral Hypoperfusion in Hereditary Coproporphyria (HCP): A Single Photon Emission Computed Tomography (SPECT) Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Inhibition of Candida rugosa Lipase by Secondary Metabolites Extracts of Three Algerian Plants and their Antioxydant Activities
Current Enzyme Inhibition Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Vascular Dysfunction in Obesity and Insulin Resistance)
Current Vascular Pharmacology Editorial (Thematic Issue: Mechanistic Biomarkers: The Field for the Development of Non-Pharmaceutical and Pharmaceutical Approaches to Diagnostics, Prevention and Treatment of Chronic Diseases)
Current Pharmaceutical Design Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design